Peter Feinberg - 12 Jan 2026 Form 4 Insider Report for Immuneering Corp (IMRX)

Role: Director
Signature: /s/ Michael D. Bookman, Attorney-in-Fact for Peter Feinberg
Issuer symbol: IMRX
Transactions as of: 12 Jan 2026
Net transactions value: +$86,904
Form type: 4
Filing time: 14 Jan 2026, 08:10:34 UTC
Previous filing: 02 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Feinberg Peter	Director	245 MAIN STREET, SECOND FLOOR, CAMBRIDGE	/s/ Michael D. Bookman, Attorney-in-Fact for Peter Feinberg	14 Jan 2026	0001870076

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IMRX	Class A Common Stock	Purchase	$86,904	+20,000	+17%	$4.35	135,441	12 Jan 2026	General Partner of S4K Investments LLC.	F1
holding	IMRX	Class A Common Stock						156,766	12 Jan 2026	Direct
holding	IMRX	Class A Common Stock						392,242	12 Jan 2026	General Partner of PF Associates L.P.
holding	IMRX	Class A Common Stock						476,615	12 Jan 2026	General Partner of PEF LLC.

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.315 to $4.38. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.